Form 4: Caris Life Sciences Executive Reports Significant Stock Transactions and Option Grant

John Russel Denton, Senior Vice President, General Counsel, and Secretary of Caris Life Sciences, Inc., reported multiple transactions including stock dispositions for debt repayment, restricted stock unit awards, and stock option grants, alongside a reverse stock split.

Summary

• John Russel Denton, Senior Vice President, General Counsel, and Secretary of Caris Life Sciences, Inc., reported changes in his beneficial ownership of company securities.
• On March 3, 2025, Denton disposed of 238,230 shares of Common Stock at a price of $18.6 per share, which represented shares surrendered to the Issuer as repayment for an outstanding promissory note.
• On June 18, 2025, Denton acquired 99,321 shares of Common Stock at a price of $0, representing an award of restricted stock units.
• On June 20, 2025, Denton acquired 7,500 shares of Common Stock through a purchase at a price of $21 per share.
• On March 3, 2025, Denton was granted 255,000 stock options with an exercise price of $18.6 per share, which will expire on March 3, 2035.
• The stock options vested 60% at grant, with an additional 20% vesting on September 1, 2025, and the final 20% vesting on September 1, 2026.
• All securities reported in this Form 4 reflect a one-for-four reverse stock split that was effected as of June 1, 2025.
• Following these transactions, Denton directly beneficially owns 123,591 shares of Common Stock and 255,000 stock options.
• Additionally, Denton indirectly beneficially owns 5,000 shares of Common Stock through a trust.

Sentiment

Score: 6

Explanation: The document is a factual report of insider transactions. While there's a disposition for debt repayment, the acquisitions of RSUs, stock options, and a direct share purchase indicate positive alignment and confidence from a key executive, slightly leaning positive.

Positives

• Acquisition of 99,321 shares of Common Stock through a restricted stock unit award, indicating ongoing equity compensation.
• Direct purchase of 7,500 shares of Common Stock at $21 per share, demonstrating management's confidence in the company's valuation.
• Grant of 255,000 stock options, providing long-term incentive and alignment with shareholder interests.

Negatives

• Disposition of 238,230 shares of Common Stock at $18.6 per share for the repayment of an outstanding promissory note, which reduces direct share ownership.

Future Outlook

The stock options granted to John Russel Denton will continue to vest, with 20% vesting on September 1, 2025, and another 20% on September 1, 2026, aligning his incentives with the company's long-term performance.

Management Comments

• John Russel Denton holds the positions of Senior Vice President, General Counsel, and Secretary at Caris Life Sciences, Inc.

Industry Context

This Form 4 filing details specific insider transactions for Caris Life Sciences, Inc. and does not provide information on broader industry trends or competitive landscape. It is a routine disclosure of changes in beneficial ownership by a key executive.

Related Party Transactions

• Disposition of 238,230 shares of Common Stock to the Issuer as repayment for an outstanding promissory note.

Stakeholder Impact

• Shareholders: Insider transactions, particularly purchases and option grants, can be viewed as a signal of management's confidence in the company's future prospects. The reverse stock split impacts the number of shares outstanding and per-share metrics.
• Employees: The grant of restricted stock units and stock options to a senior executive is a common form of compensation, aligning management incentives with company performance.

Next Steps

• Continued vesting of John Russel Denton's stock options on September 1, 2025, and September 1, 2026.

Key Dates

Keywords

Caris Life Sciences, CAI, SEC Form 4, Insider Trading, Stock Options, Restricted Stock Units, Reverse Stock Split, John Russel Denton, Beneficial Ownership